Nutriband secures $2M credit line for AVERSA Fentanyl commercialization

NutriBand Inc.

Three-year $2,000,000 credit line at 7% interest, non-convertible to common stock.
Proceeds to fund FDA approval process and commercial manufacturing of AVERSA Fentanyl.
AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system using proprietary technology.
Potential peak annual US sales estimated at $80M-$200M per 2022 market analysis.
Financing is non-dilutive, supporting growth strategy without equity dilution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.